VANCOUVER, BC / ACCESS Newswire / July 7, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:XPHYF)(FSE:4XT), a bioscience innovator specializing in advanced drug delivery systems ...

One of the fundamental barriers to equitable neurological care is the historic male bias in clinical research. For decades, ...

Lindsay Malone, MS, RDN, LD, is a registered dietitian specializing in lifestyle medicine. She works as an integrative and ...

Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging ...

Nonetheless, recent research investigating clinical and genetic factors associated with benign MS has found that patients categorised as benign tend to experience favourable progression across ...

Curcumin, the active compound in turmeric, may help protect against esophageal damage caused by GERD. It has a wide range of ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Illinois engineers fused ultrafast imaging with smart algorithms to peek at living brain chemistry, turning routine MRIs into ...

A trial using PET scans to test the anti-inflammatory drug PIPE-791 finished enrolling healthy volunteers and patients with ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential ...

Background: Multiple myeloma (MM) is the second most common hematological malignancy that still lacks effective clinical treatments. In particular, MM with central nervous system (CNS) invasion occurs ...

To quantify antibiotics in ICU patients’ blood, dried blood spot analysis was sued alongside UHPLC–MS/MS to monitor these substances in a more convenient matter.